Intensity Therapeutics Inc INTS

$3.10 -0.40 (-11.43%)

Valuation

Market cap: 11,427,000
Revenue TTM: $0
Net income TTM: $-11,610,000
P/E (trailing): 0.00
P/E (forward): —
Profit margin: 0.00%
Debt to equity: 0.00

Trading

Volume: 50,200
Avg volume: 18,580
Day's range: $2.80 – $3.32
Shares out: 3,265,000
Stochastic %K: 39%
Beta: 2.78
Analysts: Moderate Buy
Price target: $18.50

Price

Company profile

Intensity Therapeutics, Inc., a late-stage clinical biotechnology company, engages in the provision of treatment for the regional and systemic nature of cancer relapse and metastasis in the United States. Its lead product candidate includes INT230-6, which is in Phase 3 clinical studies for the treatment of soft tissue sarcoma; and neoadjuvant and metastatic triple negative breast cancer which is in Phase 2 clinical...

Industry: Biotechnology
Sector: Healthcare
Phone: 203 221 7381
Website: https://intensitytherapeutics.com
Address: 1 Enterprise Drive, Suite 430, Shelton, United States

Latest news

No headlines yet.

Stocktwits

mikejohns777 Nov 5, 7:23 PM

$INTS 💩 Tax-loss harvesting and shorting is the only long term option with this garbage.

0 replies

flychicken1991 Nov 5, 2:42 PM

$INTS Intensity Therapeutics Reports Third Quarter 2026 Financial Results and Provides Business Update. Impact: Mixed (81%). Resuming INT230-6 trials can support INTS's price by reducing development-delay risk, while higher research spending and funding-dependent expansion pressure its price through potential additional equity dilution. Source and what to watch next: https://nimpact.tech/newsimpact/news/518d15a6a5c9e51f/ints-intensity-therapeutics-reports-third-quarter-2026-financial-results?utm_source=stocktwits&utm_medium=story_url

0 replies

GPin Nov 5, 2:32 PM

$CADL $INTS Lewis Bender, CEO at Intensity Therapeutics and Paul-Peter Tak, president, CEO and board director at Candel Therapeutics. Explore how intratumoral therapies trigger systemic anti-cancer immunity from a local injection, and redefine a foundational platform in immuno-oncology. 20 minute Podcast. https://www.biospace.com/drug-development/beyond-the-needle-the-future-of-intratumoral-therapy

0 replies